Who We Are

Titan is a specialty pharmaceuticals company that develops therapeutics for select chronic diseases utilizing its innovative, long-term, continuous drug delivery platform, ProNeura. The company's lead product is Probuphine, a six-month buprenorphine implant for the maintenance treatment of opioid addiction. The U.S. Food and Drug Administration approved Probuphine on May 26, 2016. Probuphine is the first marketed product to provide maintenance treatment of opioid addiction continuously for six months following a single administration procedure.

Learn More

ProNeura™ is a Proprietary, Long-Term, Continuous Drug Delivery Platform

The ProNeura long-term, continuous drug delivery platform is ideal for treating chronic diseases for which maintaining non-fluctuating medication levels may offer advantages over other routes of administration.

Learn More About ProNeura

Product Pipeline

PROBUPHINE® (buprenorphine) Implant

for the treatment of Opioid Addiction

Market completed
Market completed
Market completed
Market completed
Market in progress
Preclinical Phase 1 Phase 2 Phase 3 Market
More About PROBUPHINE® (buprenorphine) Implant

Product Pipeline

Ropinirole Implant

for the treatment of Parkinson's Disease

Phase 1 completed
Phase 1 in progress
Phase 1 not started
Phase 1 not started
Phase 1 not started
Preclinical Phase 1 Phase 2 Phase 3 Market
More About Ropinirole Implant

Product Pipeline

T3 Implant

for the treatment of Hypothyroidism

Preclinical in progress
Preclinical not started
Preclinical not started
Preclinical not started
Preclinical not started
Preclinical Phase 1 Phase 2 Phase 3 Market
More About T3 Implant

Intellectual Property

Titan has a broad intellectual property portfolio that protects the ProNeura drug delivery platform, with issued patents and patent applications covering formulations and methods related to the treatment of chronic diseases, including opioid addiction and Parkinson's disease.

View IP Portfolio

Strategic Alliances

Titan has extensive expertise in pharmaceutical product development and plans to pursue commercial partnerships at the appropriate time in the development cycle of its products, adding value to Titan in the short- and the long-term. In 2012, Titan licensed the commercial rights to Probuphine in the U.S. and Canada to Braeburn Pharmaceuticals, valued at over $200 million in milestone payments, excluding tiered royalties in the mid-teen to low twenty percent of net sales.

Read More About Strategic Alliances

Leadership

Titan Pharmaceuticals' executive team has more than 75 years of collective experience in the pharmaceutical industry.

View Management Team View Board of Directors

Latest News

January 13, 2020
Titan Pharmaceuticals Announces Addition Of Probuphine® To Federal Supply Schedule

SOUTH SAN FRANCISCO, Calif., Jan. 13, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced that it has signed an agreement for Probuphine (buprenorphine) implant to be included on the Federal Supply Schedule ("FSS"), providing U.S. veterans and other federal government agencies with access to Titan's novel 6-month maintenance treatment for O

Read Press Release
January 7, 2020
Titan Pharmaceuticals Announces Pricing of $2.2 Million Registered Direct Offering
December 30, 2019
Titan Pharmaceuticals Appoints Dr. Kate DeVarney To Its Board Of Directors
View all Press Releases